Harbor Capital Advisors, Inc. Ascendis Pharma A/S Transaction History

Harbor Capital Advisors, Inc.

$1.31 Billion
Q2 2024

A detailed history of Harbor Capital Advisors, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 52,200 shares of ASND stock, worth $7.64 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

52,200

Previous 22,006 137.21%

Holding current value

$7.64 Million

Previous $3.33 Million 113.98%

% of portfolio

0.54%

Previous 0.43%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	BUY	$121.07 - $153.67 $3.66 Million - $4.64 Million	30,194 Added 137.21%	52,200 $7.12 Million
Q1 2024 May 13, 2024	BUY	$123.45 - $159.4 $1.22 Million - $1.58 Million	9,921 Added 82.09%	22,006 $3.33 Million
Q4 2023 Jan 08, 2024	SELL	$86.1 - $127.36 $176,505 - $261,088	-2,050 Reduced 14.5%	12,085 $1.52 Million
Q3 2023 Oct 20, 2023	BUY	$86.5 - $103.97 $180,958 - $217,505	2,092 Added 17.37%	14,135 $1.32 Million
Q2 2023 Jul 11, 2023	SELL	$69.96 - $97.84 $11,053 - $15,458	-158 Reduced 1.29%	12,043 $1.07 Million
Q1 2023 Apr 26, 2023	SELL	$104.9 - $126.78 $105,844 - $127,921	-1,009 Reduced 7.64%	12,201 $1.31 Million
Q4 2022 Jan 20, 2023	SELL	$99.42 - $131.97 $28,334 - $37,611	-285 Reduced 2.11%	13,210 $0
Q3 2022 Oct 28, 2022	SELL	$84.03 - $110.23 $125,372 - $164,463	-1,492 Reduced 9.96%	13,495 $1.39 Million
Q2 2022 Jul 26, 2022	SELL	$78.08 - $117.61 $3,123 - $4,704	-40 Reduced 0.27%	14,987 $1.39 Million
Q1 2022 Apr 28, 2022	SELL	$102.18 - $135.75 $223,672 - $297,156	-2,189 Reduced 12.71%	15,027 $1.76 Million
Q4 2021 Feb 04, 2022	BUY	$127.1 - $169.66 $2.19 Million - $2.92 Million	17,216 New	17,216 $2.32 Million

Others Institutions Holding ASND

# of Institutions

223

Shares Held

56.5M

Call Options Held

142K

Put Options Held

259K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.16B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.

Account

Harbor Capital Advisors, Inc. Ascendis Pharma A/S Transaction History